Startups & Funding

Science Corporation Raises $400M Series D to Scale PRIMA Retinal Implant

Science Corporation's $400M Series D funds European expansion of its CE-marked PRIMA retinal implant, a US approval push, and a research-stage biohybrid neural-interface program.

Science Corporation Raises $400M Series D to Expand PRIMA Access
Science Corporation Raises $400M Series D to Expand PRIMA Accessnewarta / pixabay
By Elena Vasquez5 min read

Why it matters

  • Science Corporation raised a $400 million Series D announced November 17, 2026, bringing total funding since 2021 past $900 million.
  • PRIMA, with 378 light-powered pixels, is the first brain-computer interface CE marked in the EU to restore form vision.
  • At 12 months, 80% of PRIMA study patients showed clinically meaningful visual acuity improvement; 84% read letters and words at home.
  • PRIMA received two FDA Humanitarian Use Device designations on July 22, 2026 but still requires Humanitarian Device Exemption approval.
  • The biohybrid neural-interface program anchors hundreds of thousands of engineered neurons to a device; therapeutic uses remain undefined.

Science Corporation has raised a $400 million Series D to expand European availability of its PRIMA retinal implant, prepare for a US launch, and deepen investment in a biohybrid neural-interface program that remains firmly in the research stage. The company announced the round on November 17, 2026. The financing brings total capital raised since Science's founding in 2021 to more than $900 million.

The round drew participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, among other investors. Alongside the clinical programs, the company said it will expand its research, manufacturing and operational infrastructure.

The raise matters because it funds two very different bets at once. One is a commercial medical device with a European CE mark and promising clinical data but no US approval. The other is an experimental neural-interface architecture whose therapeutic uses are still undefined. Investors are underwriting both the near-term scaling of a vision-restoring implant and a long-horizon research program that Science claims could eventually offer far more brain-machine bandwidth than anything on the market today.

What Is PRIMA and Who Is It For?

PRIMA is a retinal implant being studied for geographic atrophy caused by dry age-related macular degeneration. Science describes it as the first brain-computer interface CE marked in the European Union to restore form vision—the ability to read letters, numbers and words—for patients blinded by certain types of late-stage macular degeneration. The device is registered for supply in the United Kingdom. It is not approved or available for sale in any other country.

The hardware works as a pair. The implant itself contains 378 light-powered pixels that convert light from the system's glasses into signals that stimulate retinal cells. The glasses combine a front-facing camera with an eye-facing projector that shines light precisely onto the implant. The design is intended to replicate the function of light-sensitive cells that patients have lost.

In other words, the implant does not replace the entire damaged retina. It substitutes for a specific population of cells, and the glasses do the work of capturing and routing the visual scene onto that substitute.

What Do the Clinical Results Show?

The headline numbers come from Science's own product page. At 12 months, 80% of patients in the PRIMA clinical study showed clinically meaningful improvement in visual acuity. And 84% reported reading letters, numbers and words at home with the system, according to the company.

One caveat sits inside the data itself. Science notes that the reported efficacy results include the use of digital zoom and contrast. That means the measured gains reflect the full system—implant, glasses and image processing—rather than raw implant performance alone.

For a patient population blinded by late-stage macular degeneration, though, the distinction may matter less than the outcome. Reading letters and words at home is a functional milestone that few late-stage geographic atrophy treatments can currently offer.

Where Does the US Approval Process Stand?

PRIMA has cleared an early regulatory hurdle in the United States, but only a hurdle. In a July 22, 2026 announcement, Science said PRIMA had received two FDA Humanitarian Use Device designations.

The program provides expedited review for devices treating rare diseases or conditions. But designation is not marketing approval. PRIMA must still be reviewed and approved through a Humanitarian Device Exemption before it can be sold in the US, and that process remains underway.

The two designations cover separate patient populations:

  • Blindness in both eyes caused by an advanced subset of geographic atrophy, without vision loss from other eye diseases
  • Vision loss from Stargardt disease, a rare inherited retinal disease

The Stargardt designation is notable because it extends PRIMA's potential reach beyond age-related macular degeneration into an inherited condition that typically strikes younger patients. Whether the Humanitarian Device Exemption pathway ends in approval will determine the pace of any US launch.

What Is the Biohybrid Neural-Interface Program?

The second half of the Series D story is more speculative. Science's biohybrid architecture takes a fundamentally different approach from the retinal implant. It anchors hundreds of thousands of engineered neurons to a device and uses their projections to form connections with neurons in the brain.

MicroLEDs stimulate the embedded neurons, which are modified through optogenetics so they can be activated by light. Electrodes record the neurons' activity. Science says this architecture can provide orders of magnitude more bandwidth than current devices while avoiding the damage and limitations associated with inserting wires into the brain.

The claim is ambitious. Traditional brain-computer interfaces rely on electrode arrays physically threaded into neural tissue, which caps channel counts and can damage the very tissue they read from. Science's design would outsource the neural interface to engineered cells grown on the device, letting biology form the connections instead of metal.

The company describes three potential research applications:

  • Language and communication
  • Motor control
  • Learning and reasoning after brain injuries

The operative word is "research." Science frames these as research applications, not products or clinical programs. No therapeutic use has been defined, and the company does not claim otherwise.

Why This Raise Fits the Moment

The financing supports two distinct stages of development. On one track sits commercial expansion of a retinal implant that already carries a CE mark, has UK registration, and has posted 12-month clinical results—yet still seeks US approval through a Humanitarian Device Exemption review. On the other track sits continued development of a separate neural-interface architecture whose therapeutic uses remain research objectives.

That structure puts Science in an unusual position among neurotechnology companies. It is not a pure research shop burning cash toward an uncertain first product, and it is not a device maker with a single commercial SKU and nothing behind it. The $400 million buys capacity on both fronts: wider PRIMA access in Europe and the UK, the regulatory push toward a US launch, and the manufacturing and research infrastructure to keep the biohybrid program moving.

The near-term test is regulatory. If the FDA approves the Humanitarian Device Exemption, PRIMA becomes one of the first form-vision-restoring implants available to US patients with advanced geographic atrophy or Stargardt disease. If it does not, the company still has its European commercial base and more than $900 million in lifetime funding to fall back on. The biohybrid program, meanwhile, will be judged on papers and milestones, not product pages, for years to come.

Source: unite.ai

Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Market editor covering technology and product news in artificial intelligence and machine learning at AI In Context.

708 articles

Related articles

  1. Science Corporation implants vision chip in first Stargardt patient
  2. Isomorphic Labs Raises $5B as AI Drug Design Faces Trial Test
  3. Synchron Halts Brain Implant Trials Over Signal-Cable Flaw
  4. Isomorphic Labs raises $5B to push AI-designed drugs into trials
  5. Astromech Buys Form Bio for $230 Million to Fuse Evolutionary AI With Gene Design

« Previous articleNext article »